A Systematic Review of the Emerging Treatment for Hepatorenal Syndrome With a Principal Focus on Terlipressin: A Recent FDA-Approved Drug

Background: Hepatorenal syndrome (HRS), a consequence of liver cirrhosis, is the development of renal failure, which carries a grave prognosis. Reversing acute renal failure with various vasoconstrictor therapies at an appropriate time favors a good prognosis, especially when a liver transplant is n...

Descripción completa

Detalles Bibliográficos
Autores principales: Thangaraj, Santhosh Raja, Srinivasan, Mirra, Arzoun, Hadia, Thomas, Siji S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445509/
https://www.ncbi.nlm.nih.gov/pubmed/37621788
http://dx.doi.org/10.7759/cureus.42367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445509/
https://www.ncbi.nlm.nih.gov/pubmed/37621788
http://dx.doi.org/10.7759/cureus.42367

Ejemplares similares